Bio-Techne price target lowered to $60 from $75 at Stifel

Stifel lowered the firm’s price target on Bio-Techne (TECH) to $60 from $75 and keeps a Hold rating on the shares. Growth is expected to step down to the low-single digit range in fiscal Q4, notes the analyst, who sees Bio-Techne as “somewhat caught between trying to lower expectations in a way that derisks the outlook while still signaling growth possibilities that can yield top-line differentiation.”